Equities research analysts expect Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to report sales of $19.20 million for the current quarter, according to Zacks. Five analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from $14.32 million to $23.00 million. The company is expected to issue its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full-year sales of $77.75 million for the current year, with estimates ranging from $59.83 million to $97.20 million. For the next fiscal year, analysts expect that the firm will post sales of $131.00 million, with estimates ranging from $93.36 million to $233.30 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Monday, May 13th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.12. The business had revenue of $12.45 million during the quarter, compared to analyst estimates of $2.40 million. During the same period in the prior year, the firm earned ($0.06) EPS.
A number of equities analysts have commented on CPRX shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Catalyst Pharmaceuticals in a report on Tuesday, March 19th. ValuEngine raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, March 25th. BidaskClub raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 27th. HC Wainwright set a $9.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, May 14th. Finally, Zacks Investment Research raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Tuesday, May 21st. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $7.35.
In related news, CEO Patrick J. Mcenany bought 25,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were bought at an average cost of $3.23 per share, for a total transaction of $80,750.00. Following the completion of the purchase, the chief executive officer now owns 4,762,693 shares of the company’s stock, valued at approximately $15,383,498.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.70% of the company’s stock.
A number of hedge funds have recently bought and sold shares of CPRX. Broadfin Capital LLC lifted its stake in Catalyst Pharmaceuticals by 22.0% in the fourth quarter. Broadfin Capital LLC now owns 6,268,298 shares of the biopharmaceutical company’s stock valued at $12,035,000 after buying an additional 1,132,034 shares during the last quarter. Kennedy Capital Management Inc. bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at about $5,099,000. BlackRock Inc. raised its stake in shares of Catalyst Pharmaceuticals by 11.5% during the fourth quarter. BlackRock Inc. now owns 6,970,873 shares of the biopharmaceutical company’s stock valued at $13,384,000 after purchasing an additional 719,093 shares in the last quarter. EAM Global Investors LLC bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at about $1,409,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Catalyst Pharmaceuticals by 58.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 413,520 shares of the biopharmaceutical company’s stock valued at $795,000 after purchasing an additional 151,738 shares in the last quarter. Institutional investors own 59.79% of the company’s stock.
Catalyst Pharmaceuticals stock traded up $0.11 during mid-day trading on Monday, reaching $3.84. The company’s stock had a trading volume of 1,117,827 shares, compared to its average volume of 1,509,277. The company has a market capitalization of $383.65 million, a price-to-earnings ratio of -11.64 and a beta of 2.71. The firm’s 50 day moving average is $3.58. The company has a current ratio of 6.08, a quick ratio of 6.07 and a debt-to-equity ratio of 0.02. Catalyst Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $6.16.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Featured Story: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.